By Greg Hazley
Revamping biotechnology company Dendreon has brought in Lindsay Rocco to head corporate communications.
Rocco |
Rocco takes an executive VP title reporting to chairman and CEO John Johnson, who joined in February from Savient Pharmaceuticals. Rocco was previously senior VP at Omnicom’s Rx Mosaic Health and, earlier, director of public affairs at Roche-Genentech.
The Seattle-based developer of prostate cancer drug Provenge is in the midst of a $150M cost-cutting plan that includes cutting 600 jobs and closure of a manufacturing plant as it shifts sales and marketing operations to Bridgewater, N.J. Third-quarter revenue was up 21 percent, including a 27% increase from the two-year-old prostate cancer treatment to $77.9M. Its quarterly loss soared to $154.9M on the restructuring and analysts noted Provenge sales are falling well short of goals.
Rocco, based in New Jersey, said she is “honored” to join Dendreon at “such an important time for the company.”
Katherine Stueland previously led corporate comms. and IR from Seattle.
Joele Frank, Wilkinson Brimmer Katcher works with Dendreon.
Shares are trading around $4, at the lower end of its $3.69-$17.04 52-week range. |